Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BND-003
- Development stage
- Unknown
- Lead developer
- BeyondBio
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
BND-003 is an orally bioavailable small molecule inhibitor of CDC-like kinases (CLK) and dual-specificity tyrosine-regulated kinases (DYRK), specifically DYRK1A, developed by BeyondBio. It is being developed as a disease-modifying treatment for Alzheimer's disease and other tauopathies. The drug's mechanism of action involves the modulation of RNA splicing for the Tau protein and the inhibition of Tau hyperphosphorylation, which are key processes in the formation of neurofibrillary tangles. By stabilizing microtubules and reducing neurotoxic Tau species, BND-003 aims to slow or halt the progression of cognitive decline. It has shown promising results in preclinical studies regarding blood-brain barrier penetration and reduction of amyloid-beta and Tau pathology, and it is currently in Phase 2 clinical development.
- Other names
- BND003BND-003BND 003
02
Targets
CLK4DYRK1A (Dual-specificity tyrosine-phosphorylation-regulated kinase 1A)CLK2 (CDC-like kinase 2)CLK1 (CDC-like kinase 1)
Beyond the preview
Go deeper on BND-003.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BND-003.